{"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"<0.0001","statisticalComment":"Stratified by Previous biologic agent and/or JAK inhibitors exposure, Use of oral corticosteroids treatment at Week 0, Clinical remission at Week 10.","statisticalMethod":"Cochran-Mantel-Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"118"},{"groupId":"OG001","value":"20"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"231"},{"groupId":"OG001","value":"112"}],"units":"Participants"}],"description":"Endoscopic response was defined as a 50% decrease in Simplified Endoscopic Activity Score for Crohn's Disease (SES-CD) score from the baseline value.\n\nThe SES-CD assesses the size of mucosal ulcers, ulcerated surface, endoscopic extension and the presence of stenosis. Each item is scored from 0-3, with total score from 0-60. Higher score indicates more severe endoscopic activity.\n\nPatients with dose adjustment to CT-P13 SC 240 mg prior to Week 54 were considered as non-responder.\n\nStatistical testing for this outcome based on the colonoscopy (SES-CD) was conducted using the colonoscopy reading results of central level.","groups":[{"description":"CT-P13 SC 120 mg","id":"OG000","title":"CT-P13 SC 120 mg"},{"description":"Placebo","id":"OG001","title":"Placebo"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All-randomized population","reportingStatus":"POSTED","timeFrame":"Week 54","title":"Percentage of Patients Achieving Endoscopic Response (Based on Central SES-CD) at Week 54","type":"PRIMARY","unitOfMeasure":"Participants"}